AADI: רווח נקי למניה ב-12 החודשים האחרונים Aadi Bioscience

Aadi Bioscience develops targeted treatments for rare oncological diseases. The company's current stability depends on test results, as it lacks operating income. Growth of the client base is regulated by the FDA, while patient retention remains maximal due to a lack of alternatives. The trailing 12-month earnings per share highlight the effect of the patent margin for mTOR inhibitors, with the indicator value standing at -2.29.

The scale of Aadi Bioscience operations is determined by the commercialization stage of the Fyarro targeted therapy. This indicator is calculated by dividing the total annual net income by the total number of shares outstanding. The metric measures the actual cash efficiency of the business, filtering out market noise. For a company with a high scientific reputation, this figure reflects the transition from investment to profitability. By analyzing the net income per share over the last 12 months, an investor assesses the asset's fundamental margin of safety.